Robert D. Madder

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Carel W. le Roux, Rafael Violante Ortíz, Trine Vang Skjøth, Linda Shapiro Manning et autres

ie, gb, dk, us, ca, be, mx, fr (code pays fourni par la source)

Abstract 223: Innovations in Quality Improvement

Nicole Ansani-Jankowski, Robert D. Madder

Innovative Medical Platform Optimizing Research and Technology (IMPORT)> Background: A medical group, pharmaceutical company, and data harvesting and integration company collaborated to test an innovative approach to quality improvement (QI) that utilizes clinical expertise, advanced outcomes analytics, electronic medical records (EMR), and …

us (code pays fourni par la source)

Efficacy and Safety of Fixed Combinations of Irbesartan/Hydrochlorothiazide in Older vs Younger Patients With Hypertension Uncontrolled With Monotherapy

William C. Cushman, Joel M. Neutel, Elijah Saunders, George L. Bakris et autres

Subgroup analysis of the Irbesartan/Hydrochlorothiazide Blood Pressure Reductions in Diverse Patient Populations (INCLUSIVE) trial evaluated the efficacy and safety of irbesartan/hydrochlorothiazide (HCTZ) fixed combinations in patients aged 65 years or older with uncontrolled systolic blood pressure (SBP) after >or= 4 weeks of …

us (code pays fourni par la source)

Repaglinide Versus Nateglinide Monotherapy

Julio Rosenstock, David Hassman, Robert D. Madder, Shari A. Brazinsky et autres

OBJECTIVE: A randomized, parallel-group, open-label, multicenter 16-week clinical trial compared efficacy and safety of repaglinide monotherapy and nateglinide monotherapy in type 2 diabetic patients previously treated with diet and exercise. RESEARCH DESIGN AND METHODS: Enrolled patients (n = 150) had received treatment …

us (code pays fourni par la source)

Porównanie monoterapii repaglinidem i nateglinidem. Wieloośrodkowe badanie randomizowane

Julio Rosenstock, David Hassman, Robert D. Madder, Shari A. Brazinsky et autres

INTRODUCTION. A randomized, parallel-group, openlabel, multicenter 16-week clinical trial compared efficacy and safety of repaglinide monotherapy and nateglinide monotherapy in type 2 diabetic patients previously treated with diet and exercise. MATERIAL AND METHODS. Enrolled patients (n = 150) had received treatment with …

us (code pays fourni par la source)